Search

Objective: During clinical practice, it can be challenging, given the lack of response biomarkers, to identify the patients with metastatic breast cancer (mbca) who would benefit most from the addition of bevacizumab to first-line standard chemotherapy. The aim of the present review was to summarize the relevant scientific evidence and to discuss the experience of a group of experts in using bevacizumab to treat mbca., Methods: A panel of 17 Spanish oncology experts met to discuss the literature and their experience in the use of bevacizumab as first-line treatment for mbca. During the meeting, discussions focused on three main issues: the profile of the patients who could benefit most from bevacizumab, the optimal bevacizumab treatment duration, and the safety profile of bevacizumab., Results: The subset of mbca patients who would benefit the most from the addition of bevacizumab to first-line standard chemotherapy are those with clinically defined aggressive disease. Treatment with bevacizumab should be maintained until disease progression or the appearance of unacceptable toxicity. In the mbca setting, the toxicity profile of bevacizumab is well known and can be managed in clinical practice after adequate training., Conclusions: This expert group recommends administering bevacizumab as first-line treatment in patients with clinically aggressive disease.

A case is presented of PES of the small intestine debuting with subocclusive crises. After the preoperative study the patient was diagnosed as probable neoplasm of the small intestine. In the operation was confirmed an annular stenosing ileal tumor that respected the serosa. Ample intestinal resection was practiced with a normal postoperative recovery. The pathology report indicated plasmocytoma, the immunoperoxidase technique being negative. The existence of multiple myeloma and other lesions at a distance was excluded. Almost a year after the operation the patient remains asymptomatic and free of recurrence. A review of the literature is offered.